Liza Destiny ready for topside modules

Must Read

OilNOW
OilNOW
OilNOW is an online-based Information and Resource Centre

Dutch floater specialists SBM Offshore says work on the 1.6-million-barrel capacity Floating Production Storage and Offloading (FPSO) vessel – Liza Destiny, is progressing on schedule with all systems in place for delivery in 2019.

SBM said that after finishing the first dry dock session, the project has entered an important phase with concurrent activities in hull conversion, module fabrication, and package delivery. In Guyana, work is underway with respect to operations readiness while reviewing ways to maximize local content.

“Work on FPSO Liza Destiny is progressing in accordance with project schedule. The second (and last) dry-dock session was successfully completed and the vessel is now ready to receive its topside modules,” the company stated in its Q3 Trading Update released on November 15.

The company said Fast4WardTM, as a product offering, is maturing in the market and It forms the design basis for the second ExxonMobil Liza FPSO project, which is moving from concept to reality and predicated on SBM’s first Fast4WardTM hull. “On the basis of increased client interest and better demand visibility, SBM Offshore is pleased to confirm the commitment to build its second Fast4WardTM hull with the SWS yard,” the floater specialist said.

The steel cutting for the first hull was held at the SWS yard in Shanghai, China in March 2018, and if all goes according to plan, the first Fast4Ward FPSO could be deployed for Exxon in Guyana, as per the FEED deal signed in July this year, making the FPSO SBM’s largest-ever such unit, able to 2 million barrels of crude oil.

The Liza Destiny will produce up to 120,000 barrels of oil per day from the Liza Phase 1 development while the second FPSO for the giant Liza Phase 2 project would have double the capacity and will be able to store around 2 million barrels of crude oil.

- ADVERTISEMENT -
spot_img

Partnered Events

Latest News

Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel...

More Articles Like This